Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
SOUTH PLAINFIELD, N.J. and ROCHESTER, N.Y., May 09, 2017 -- Today, the University of Rochester School of Medicine and Dentistry and Admera Health announced that enrollment had commenced in a randomized clinical study evaluating the use of pharmacogenomics to guide pain management decisions related to acute dental surgery. Specifically, the study is seeking to determine if a preoperative chair-side pharmacogenomic algorithm can significantly enhance the efficacy of surgical pain management and to characterize the association between gene-drug interactions and clinical outcomes.
Admera Health, a molecular diagnostic company, will extract and sequence DNA samples provided by the University of Rochester. Sequencing will utilize Admera’s PGxOne™ Plus test, a 50 gene Next Generation Sequencing panel that interrogates nearly 200 different variants and provides recommendations for over 220 drugs based on an individual’s unique genetic makeup.
“It is well understood in the medical community that most acute surgical pain methods have shown inconsistent effects on pain relief and rely excessively on opioid use, which has associated dependency issues,” as stated by Admera CEO and President Guanghui Hu. “With the implementation of our PGxOne™ Plus test, we are confident that this study will demonstrate improved patient outcomes, similar to the way pharmacogenomics has been clinically validated in other therapeutic areas such as cardiovascular health, oncology, and psychiatric care. That is why we are excited to be working with the University of Rochester for this study.”
According to the CDC, opioid-involved deaths continue to increase and have reached epidemic status. In March, a United States Senate committee opened a probe into the practices of the top manufacturers of opioid drugs.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
